DBV TECHNOLOGIE/S (NASDAQ:DBVT) Lowered to “Sell” at BidaskClub

DBV TECHNOLOGIE/S (NASDAQ:DBVT) was downgraded by equities researchers at BidaskClub from a “hold” rating to a “sell” rating in a research note issued on Friday, BidAskClub reports.

Several other equities research analysts have also weighed in on DBVT. Zacks Investment Research lowered DBV TECHNOLOGIE/S from a “buy” rating to a “hold” rating in a research note on Wednesday, May 8th. JMP Securities reissued a “buy” rating and set a $20.00 price objective on shares of DBV TECHNOLOGIE/S in a research note on Wednesday, March 6th. Finally, Stifel Nicolaus reissued a “hold” rating and set a $10.00 price objective on shares of DBV TECHNOLOGIE/S in a research note on Wednesday, March 6th. Two analysts have rated the stock with a sell rating, five have given a hold rating and four have given a buy rating to the company. DBV TECHNOLOGIE/S presently has a consensus rating of “Hold” and an average target price of $14.75.

DBVT opened at $8.36 on Friday. The firm has a market cap of $506.65 million, a PE ratio of -2.47 and a beta of 1.99. The company has a debt-to-equity ratio of 0.01, a current ratio of 3.34 and a quick ratio of 3.30. DBV TECHNOLOGIE/S has a fifty-two week low of $3.60 and a fifty-two week high of $25.77.

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. First Midwest Bank Trust Division lifted its holdings in shares of DBV TECHNOLOGIE/S by 14.5% in the first quarter. First Midwest Bank Trust Division now owns 1,131,884 shares of the company’s stock valued at $8,727,000 after purchasing an additional 142,993 shares in the last quarter. OLD Mission Capital LLC lifted its holdings in shares of DBV TECHNOLOGIE/S by 1,278.6% in the fourth quarter. OLD Mission Capital LLC now owns 143,338 shares of the company’s stock valued at $920,000 after purchasing an additional 132,941 shares in the last quarter. Exane Asset Management lifted its holdings in shares of DBV TECHNOLOGIE/S by 46.4% in the first quarter. Exane Asset Management now owns 205,000 shares of the company’s stock valued at $1,581,000 after purchasing an additional 65,000 shares in the last quarter. Bailard Inc. purchased a new stake in shares of DBV TECHNOLOGIE/S in the first quarter valued at $2,675,000. Finally, Bank of New York Mellon Corp lifted its holdings in shares of DBV TECHNOLOGIE/S by 334.1% in the fourth quarter. Bank of New York Mellon Corp now owns 1,645,000 shares of the company’s stock valued at $10,561,000 after purchasing an additional 1,266,041 shares in the last quarter. Institutional investors own 46.56% of the company’s stock.

About DBV TECHNOLOGIE/S

DBV Technologies SA, a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its lead product candidate is Viaskin Peanut, an immunotherapy product, which has completed Phase III clinical trial for the treatment of peanut allergies in children, adolescents, and adults.

Further Reading: What type of investment options does a Roth IRA provide?

Analyst Recommendations for DBV TECHNOLOGIE/S (NASDAQ:DBVT)

Receive News & Ratings for DBV TECHNOLOGIE/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DBV TECHNOLOGIE/S and related companies with MarketBeat.com's FREE daily email newsletter.